All In Biotech

Drug Trial Radar · NCT04497116

Study of RP-3500, Camonsertib, in Advanced Solid Tumors

Phase 1/2a Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-3500 Alone or in Combination With Talazoparib or Gemcitabine in Advanced Solid Tumors With ATR Inhibitor Sensitizing Mutations (TRESR Study)

Last checked: Nov 20, 2026Latest source record: Oct 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

276

Actual

Start

Jul 22, 2020

Primary completion

Jun 13, 2025

Study completion Jun 13, 2025

Sponsor

Lead sponsor
Repare TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 4, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to define the maximum tolerated dose (MTD) and determine a recommended Phase 2 dose (RP2D) and schedule of orally-administered RP-3500 (camonsertib) alone or in combination with talazoparib, a PARP inhibitor, or Gemcitabine in patients with advanced solid tumors with ATR inhibitor-sensitizing mutations. This study will also evaluate the safety and tolerability of RP-3500 (camonsertib) alone or in combination with talazoparib or gemcitabine, examine both the pharmacokinetics (PK)and pharmacodynamics (PD)and investigate its anti-tumor activity in solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • RP-3500 (camonsertib)Drug

    Oral ATR inhibitor

  • TalazoparibDrug

    Oral PARP inhibitor

  • Gemcitabine InjectionDrug

    Gemcitabine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of Treatment-Related Adverse Event of CTCAE Grade 3 and AboveTime frame: Start of treatment to 30 days post last dose, up to 1 year
  2. Frequency of Dose Limiting Toxicity (DLT)Time frame: Either 21 days or 28 days (1 cycle) from the initiation of the study treatment.

Locations

13 sites in 4 countries. Site status is shown where the registry gives one.

  • #1014, Northwestern University

    Chicago, Illinois

  • #1006, Massachusetts General Hospital

    Boston, Massachusetts

  • #1002, Dana Farber Cancer Institute

    Boston, Massachusetts

  • #1004, Memorial Sloan Kettering Cancer Institute

    New York, New York

  • #1005, Duke Cancer Institute

    Durham, North Carolina

  • #1007, Rhode Island Hospital

    Providence, Rhode Island

  • #1003, Sarah Cannon Research Institute

    Nashville, Tennessee

  • #1001, The University of Texas M.D. Anderson Cancer Center

    Houston, Texas

  • #2001, Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • #4001, Copenhagen University Hospital Rigshospitalet - Blegdamsvej

    Copenhagen, DK, Denmark

  • #3003, Sarah Cannon Research Institute

    London, United Kingdom

  • #3001, The Christie NHS Foundation Trust

    Manchester, United Kingdom

  • #3002, Freeman Hospital Newcastle

    Newcastle upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.